SCHEMBL560366

SCHEMBL560366

NC[C@H](CC(=O)O)c1ccc(Cl)c(OCc2cccnc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 3/20 0.46
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
LMNA P02545 4/20 0.45
HTT P42858 2/20 0.45
GFER P55789 1/20 0.45
GAA P10253 1/20 0.45
PDCD1 Q15116 7/20 0.44
CD274 Q9NZQ7 7/20 0.44
CTSA P10619 1/20 0.44
GABBR2 O75899 4/20 0.44
GABBR1 Q9UBS5 4/20 0.44
CYP2C9 P11712 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
NFKB1 P19838 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL559797 0.99 GAA (0.47) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL560020 0.87 GAA (0.48) CYP3A4CYP2D6LMNAGAACTSA
Hydrochloric Acid SCHEMBL559749 0.87 GAA (0.53) CYP3A4CYP2D6LMNAGAACTSA
Hydrochloric Acid SCHEMBL559360 0.86 GAA (0.50) CYP3A4CYP2D6LMNAGAACTSA
SCHEMBL559890 0.84 GAA (0.46) CYP3A4CYP2D6LMNAGAACTSA
Hydrochloric Acid SCHEMBL559778 0.83 GAA (0.47) CYP3A4CYP2D6LMNAGAACTSA
SCHEMBL559596 0.81 CDK5 (0.47) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL559662 0.81 MRGPRX4 (0.61) HTTMEN1KMT2ANFKB1MAPT
SCHEMBL559357 0.81 GAA (0.47) CYP3A4CYP2D6LMNAGAACTSA
Hydrochloric Acid SCHEMBL635254 0.80 GAA (0.49) CYP3A4CYP2D6LMNAGAACTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US claimed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP claimed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US claimed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US claimed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO claimed
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US disclosed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP disclosed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US disclosed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US disclosed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 CYP3A4 1948/4885CYP2D6 2297/4885SLC6A2 565/4885
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 CYP3A4 1948/4885CYP2D6 2297/4885SLC6A2 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.